RxSight, Inc. (NASDAQ:RXST) Insider Sells $154,008.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,098,781.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.

RxSight Trading Down 0.5 %

NASDAQ RXST traded down $0.23 during trading hours on Tuesday, hitting $50.29. 231,847 shares of the company’s stock traded hands, compared to its average volume of 470,852. The firm has a market capitalization of $1.86 billion, a P/E ratio of -39.91 and a beta of 1.20. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54. The business’s fifty day moving average price is $52.09 and its two-hundred day moving average price is $53.85.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. The business had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company’s revenue was up 67.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.40) earnings per share. On average, sell-side analysts expect that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RXST. Counterpoint Mutual Funds LLC raised its position in RxSight by 102.9% during the first quarter. Counterpoint Mutual Funds LLC now owns 13,573 shares of the company’s stock valued at $700,000 after purchasing an additional 6,883 shares during the period. Principal Financial Group Inc. grew its stake in shares of RxSight by 298.5% during the first quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock valued at $1,802,000 after buying an additional 26,164 shares during the last quarter. Baillie Gifford & Co. bought a new position in shares of RxSight during the first quarter valued at approximately $3,429,000. Capstone Investment Advisors LLC grew its stake in shares of RxSight by 698.4% during the first quarter. Capstone Investment Advisors LLC now owns 127,200 shares of the company’s stock valued at $6,561,000 after buying an additional 111,269 shares during the last quarter. Finally, FORA Capital LLC grew its stake in shares of RxSight by 5.6% during the first quarter. FORA Capital LLC now owns 11,695 shares of the company’s stock valued at $603,000 after buying an additional 622 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RXST. BTIG Research lifted their price target on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Stifel Nicolaus reduced their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Finally, Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.